Take a look at our previous reports:

Financial highlights

Consolidated Key Figures

(thousands of €, if not stated otherwise)

Third quarter of 2022

Third quarter of 2021

Nine months ended 30 September 2022

Nine months ended 30 September 2021

Year ended 31 December 2021

Income statement

 

 

 

 

 

Product net sales

25,135

5,691

60,491

6,147

14,753

Collaboration revenues

111,068

58,503

349,669

311,711

470,093

Cost of sales

(2,393)

(529)

(7,938)

(660)

(1,629)

R&D expenditure

(114,549)

(109,196)

(364,067)

(378,022)

(491,707)

S&M, G&A expenses

(68,677)

(45,448)

(202,686)

(151,267)

(210,855)

Other operating income

11,837

12,781

29,474

36,345

53,749

Operating loss

(37,578)

(78,199)

(135,056)

(175,747)

(165,596)

Net financial results

59,825

13,743

127,501

33,659

42,598

Taxes

(694)

(157)

(3,229)

316

(2,423)

Net profit/loss (-) from continuing operations

21,554

(64,613)

(10,784)

(141,772)

(125,422)

Net profit from discontinued operations,
net of tax

-

-

-

22,191

22,191

Net profit/loss (-)

21,554

(64,613)

(10,784)

(119,581)

(103,231)

 

 

 

 

 

 

Balance sheet

 

 

 

 

 

Cash and cash equivalents

675,519

2,834,378

675,519

2,834,378

2,233,368

Current financial investments

3,686,557

2,039,787

3,686,557

2,039,787

2,469,809

R&D incentives receivables

153,460

149,271

153,460

149,271

144,013

Assets

4,972,070

5,331,987

4,972,070

5,331,987

5,193,160

Shareholders' equity

2,690,351

2,617,383

2,690,351

2,617,383

2,643,362

Deferred income

2,052,686

2,520,652

2,052,686

2,520,652

2,364,701

Other liabilities

229,033

193,952

229,033

193,952

185,097

 

 

 

 

 

 

Cash flow

 

 

 

 

 

Operational cash burn

(125,979)

(153,546)

(343,081)

(376,743)

(564,840)

Cash flow used in operating activities

(116,942)

(136,925)

(320,682)

(340,056)

(503,827)

Cash flow generated from/used in (-) investing activities

(182,568)

311,138

(1,263,625)

993,191

541,238

Cash flow generated from/used in (-) financing activities

793

(964)

432

(2,438)

(3,876)

Increase/decrease (-) in cash and cash equivalents

(298,716)

173,249

(1,583,875)

650,697

33,535

Effect of currency exchange rate fluctuation on cash and cash equivalents

1,440

18,489

26,026

40,610

56,763

Cash and cash equivalents at the end of the period

675,519

2,834,378

675,519

2,834,378

2,233,368

Current financial investments at the end of the period

3,686,557

2,039,787

3,686,557

2,039,787

2,469,809

Total current financial investments and cash and cash equivalents at the end of the period

4,362,076

4,874,165

4,362,076

4,874,165

4,703,177

 

 

 

 

 

 

Financial ratios

 

 

 

 

 

Number of shares issued at the end of the period

65,835,511

65,530,121

65,835,511

65,530,121

65,552,721

Basic and diluted income/loss (-) per share

0.33

(0.99)

(0.16)

(1.83)

(1.58)

Share price at the end of the period (in €)

43.92

45.16

43.92

45.16

49.22

Total group employees at the end of the period (number)

1,357

1,319

1,357

1,319

1,309

Employees per site as of 30 September 2022

(total: 1,357 employees)

Employees per site as of 30 September 2022 (map)

Q3 2022 financial results

We reported product net sales of Jyseleca in Europe for the first nine months of 2022 amounting to €60.5 million (€6.1 million in the first nine months of 2021). Our counterparties for the sales of Jyseleca were mainly hospitals and wholesalers located across Europe.

Cost of sales related to Jyseleca net sales in the first nine months of 2022 amounted to €7.9 million.

Collaboration revenues amounted to €349.7 million for the first nine months of 2022, compared to €311.7 million for the first nine months of 2021.

Revenues recognized related to the collaboration agreement with Gilead for the filgotinib development were €166.8 million in the first nine months of 2022 compared to €136.4 million for the same period last year. This increase was due to a higher increase in the percentage of completion, as well as a higher revenue recognition of milestone payments strongly influenced by the milestone achieved related to the regulatory approval in Japan for UC in the first nine months of 2022.

The revenue recognition related to the exclusive access rights for Gilead to our drug discovery platform amounted to €172.6 million for the first nine months of 2022 (€173.3 million for the same period last year).

We have recognized royalty income from Gilead for Jyseleca for €8.2 million in the first nine months of 2022 (compared to €1.9 million in the same period last year) of which €3.6 million royalties on milestone income for UC approval in Japan.

Additionally, we recorded milestones of €2.0 million triggered by the first sales of Jyseleca in Czech Republic and Portugal by our distribution and commercialization partner Sobi, in the first nine months of 2022.

Our deferred income balance on 30 September 2022 includes €1.6 billion allocated to our drug discovery platform that is recognized linearly over the remaining period of our 10 year collaboration, and €0.5 billion allocated to filgotinib development that is recognized over time until the end of the development period.

Our R&D expenditure in the first nine months of 2022 amounted to €364.1 million, compared to €378.0 million for the first nine months of 2021. This decrease was primarily explained by a decrease in subcontracting costs from €189.1 million in the first nine months of 2021 to €158.5 million in the first nine months of 2022, primarily due to the winding down of the ziritaxestat (IPF) program and reduced spend on our SIKi and TYK2 programs. This was partly offset by cost increases for our filgotinib program, on a nine month basis compared to the same period in 2021. Personnel costs decreased from €134.3 million in the first nine months of 2021 to €130.0 million for the same period this year. Depreciation and impairment amounted to €35.6 million for the first nine months of 2022 (€14.1 million for the same period last year). This increase was primarily due to an impairment of €26.7 million of previously capitalized upfront fees related to our collaboration with Molecure on the dual chitinase inhibitor OATD-01 (GLPG4716), recorded in Q2 2022. 

Our S&M expenses were €105.3 million in the first nine months of 2022, compared to €46.6 million in the first nine months of 2021. This increase was primarily due to the termination of our 50/50 filgotinib co-commercialization cost sharing agreement with Gilead. The cost increase was also explained by an increase in personnel costs (€53.4 million for the first nine months of 2022 compared to €43.3 million for the same period last year) explained by an increase in the commercial work force from 234 average FTEs in the first nine months of 2021 to 304 average FTEs in the first nine months of 2022 driven by the commercial launch of filgotinib in Europe.

Our G&A expenses were €97.4 million in the first nine months of 2022, compared to €104.7 million in the first nine months of 2021. The cost decrease was primarily due to the impairment of €9.3 million on other tangible assets recorded in the first nine months of 2021 following our decision to reassess the construction project of our new future headquarter location in Mechelen (Belgium). Personnel costs amounted to €54.5 million for the first nine months of 2022 compared to €52.4 million for the same period last year.

Other operating income (€29.5 million for the first nine months of 2022, compared to €36.3 million for the first nine months of 2021) decreased by €6.9 million, mainly driven by lower grant and R&D incentive income.

We reported an operating loss amounting to €135.1 million for the first nine months of 2022, compared to an operating loss of €175.7 million for the same period last year.

Net financial income in the first nine months of 2022 amounted to €127.5 million (as compared to net financial income of €33.6 million in the same period last year). Net financial income in the first nine months of 2022 was primarily attributable to €102.1 million of unrealized currency exchange gain on our cash and cash equivalents and current financial investments at amortized cost in U.S. dollar (as compared to €54.9 million currency exchange gain on cash and cash equivalents and current financial investments in the first nine months of 2021) and €26.0 million positive changes in (fair) value of current financial investments (€7.2 million negative changes in the same period last year). The other financial expenses also contained the discounting effect of our long term deferred income of €5.7 million (€7.2 million in the same period last year). Net interest income amounted to €3.3 million in the first nine months of 2022 (compared to net interest cost of €6.3 million in the same period last year), due to increasing interest rates. The fair value loss of financial assets held at fair value through profit or loss amounted to nil in the first nine months in 2022 (as compared to €2.9 million in the same period last year).

We realized a net loss from continuing operations of €10.8 million for the first nine months of 2022, compared to a net loss of €141.8 million for the first nine months of 2021.

The net profit from discontinued operations for the first nine months of 2021 consisted of the gain on the sale of Fidelta, our fee-for-services business, for €22.2 million.

We reported a group net loss for the first nine months of 2022 of €10.8 million, compared to a group net loss of €119.6 million for the same period last year.

Cash, cash equivalents and current financial investments

Cash and cash equivalents and current financial investments totaled €4,362.1 million on 30 September 2022 (€4,703.2 million on 31 December 2021).

A net decrease of €341.1 million in cash and cash equivalents and current financial investments was recorded during the first nine months of 2022, compared to a net decrease of €295.2 million during the first nine months of 2021. This net decrease was composed of (i) €343.1 million of operational cash burn, (ii) offset by €6.7 million of cash proceeds from capital and share premium increases from exercise of subscription rights in the first nine months of 2022, (iii) €26.0 million of positive changes in (fair) value of current financial investments and €105.6 million of mainly positive exchange rate differences, and (iv) €136.4 million cash out from the acquisitions of CellPoint and AboundBio, net of cash acquired.

The operational cash burn (or operational cash flow if this liquidity measure is positive) is a financial measure that is not calculated in accordance with IFRS. Operational cash burn/cash flow is defined as the increase or decrease in our cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus:

i. the net proceeds, if any, from share capital and share premium increases included in the net cash flows generated from/used in (–) financing activities

ii. the net proceeds or cash used, if any, in acquisitions or disposals of businesses; the movement in restricted cash and movement in current financial investments, if any, the loans and advances given to third parties, if any, included in the net cash flows generated from/used in (–) investing activities

iii. the cash used for other liabilities related to the acquisition of businesses, if any, included in the net cash flows generated from/used in (–) operating activities.

This alternative liquidity measure is in our view an important metric for a biotech company in the development stage.

The following table provides a reconciliation of the operational cash burn:

 

Nine months ended 30 September

(thousands of €)

2022

2021

Increase/decrease (-) in cash and cash equivalents (excluding effect of exchange differences)

(1,583,875)

650,697

Less:

 

 

Net proceeds from capital and share premium increases

(6,695)

(2,735)

Net purchase/sale (-) of current financial investments

1,111,139

(996,008)

Cash out from acquisition of subsidiaries, net of cash acquired

115,270

-

Cash advances and loans to third parties

10,000

-

Cash used for other liabilities related to the acquisition of subsidiaries

11,080

-

Cash in from disposals of subsidiaries, net of cash disposed of

-

(28,696)

Total operational cash burn

(343,081)

(376,743)

Filgotinib
Formerly known as GLPG0634, commercial name is Jyseleca. Small molecule preferential JAK1 inhibitor, approved in RA and UC in European Union, Great Britain, and Japan. Filgotinib is partnered with Gilead. Filgotinib currently is in Phase 3 trials in CD, and in a Phase 4 trial in RA
GLPG4716
A chitinase inhibitor inlicensed from Molecure (previously OncoArendi). The rights to the molecule have been returned to Molecure in July 2022